Please login to the form below

Not currently logged in
Email:
Password:

Vectura's mystery partner licenses asthma drug for EUR 15.5m

Vectura says it could win up to EUR 15.5m after signing a licensing agreement with an unnamed international pharmaceutical company regarding its combination asthma treatment VR632

UK-based inhaleable drug company Vectura has revealed it could win up to EUR 15.5m in milestone payments, development funding and post-launch royalties after signing a licensing agreement with an unnamed international pharmaceutical company regarding its combination asthma treatment VR632.

The company, with which Vectura already has an agreement regarding its other asthma treatment VR315, will be responsible for the clinical development, manufacture and EU marketing of VR632, with Vectura having access to all clinical data generated from the collaboration.

The molecule will be developed for use with Vectura's GyroHaler inhaler device, and under the deal Vectura will be responsible for the supply of the device, along with further formulation development of VR632.

Vectura's CEO, Chris Blackwell, said: "It is a major extension to one of the three key licensing deals we have concluded for products delivered using GyroHaler and is the second announcement relating to this technology in as many months. It is also further endorsement of the added value Vectura can deliver in respiratory product development."

3rd December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics